FIP and GS-441524: how a once-fatal cat disease became curable in 84 days

In 30 seconds

Feline infectious peritonitis (FIP) was a death sentence from its first description in 1963 until 2019, when Niels Pedersen at UC Davis published cure data for an antiviral called GS-441524. The disease that once meant euthanasia at diagnosis now resolves in roughly 80 to 95 percent of cats that complete an 84-day treatment course. FIP develops when the common feline enteric coronavirus mutates inside about 5 to 10 percent of infected cats into a virulent form. It strikes young cats hardest, especially those from catteries and crowded shelters. The diagnostic catch is that no single test confirms it; the picture is built from signalment, bloodwork (low albumin-to-globulin ratio), effusion analysis, and PCR. The legal catch is that GS-441524 spent years available only through a gray market until US compounding pharmacies opened a legitimate route. A young cat with yellow effusion, a low A/G ratio, and a positive Rivalta test is a case that starts treatment now, not a case that is lost.

What FIP is and why it was 100 percent fatal until 2019

FIP is caused by a mutation of the feline enteric coronavirus (FECV), a virus that most cats carry harmlessly in the gut. In roughly 5 to 10 percent of FECV-infected cats, the virus mutates inside the body into a virulent form (FIPV) that infects macrophages and triggers a systemic granulomatous immune response.

There are two classic forms:

• Wet (effusive) FIP: accumulation of viscous yellow fluid in the abdomen, chest, or both. Vasculitis drives massive protein leakage. It progresses over weeks.
• Dry (non-effusive) FIP: granulomas in target organs (kidney, liver, eye, central nervous system). Slower to progress but equally fatal without treatment.

Mixed forms exist, along with pure ocular and neurological presentations that are especially common in young cats.

Before 2019, the prognosis was identical in every case: death in weeks to a few months. Corticosteroids, interferon, polyprenyl immunostimulant, and other palliative measures prolonged life in some cats but cured none.

Why GS-441524 changed everything

GS-441524 is a nucleoside analog that interferes with the viral RNA polymerase of the coronavirus. It is the parent molecule of remdesivir, the phosphoramidate prodrug known from COVID-19 use. The mechanism is simple: as the virus tries to copy its RNA, it incorporates GS-441524 in place of the correct nucleotide and the chain terminates.

Pedersen and colleagues at UC Davis established the fundamentals between 2018 and 2023:

• Efficacy: 80 to 95 percent of cats cured with the full 84-day protocol, depending on the form of FIP.
• Toxicity: very low at therapeutic doses. The main issue is injection-site lesions from subcutaneous dosing, which are milder when initial intravenous remdesivir is used. Liver and kidney effects are minimal and reversible.
• Dose: varies by presentation. Non-neurological dry and wet forms run about 6 to 8 mg/kg/day subcutaneously. Ocular forms run 8 to 10 mg/kg/day. Neurological forms run 10 to 15 mg/kg/day because of the blood-brain barrier.
• Duration: 84 days (12 weeks) without interruption, followed by 12 weeks of observation.

The cure is real and durable. Cats that complete the protocol and the observation window rarely relapse.

Key figures

Figure	Value	Source
FIP mortality before 2019	~100 percent	Pedersen 2018
Cure rate with full GS-441524 protocol	80 to 95 percent	Pedersen 2019-2023
Protocol duration	84 days	Pedersen 2019
Post-treatment observation without relapse	84 additional days	Pedersen 2021
Dose, wet non-neurological FIP	6 to 8 mg/kg/day SC	Pedersen 2019
Dose, neurological FIP	10 to 15 mg/kg/day SC	Pedersen 2020
Typical full-course cost, US compounded	$3,000 to $10,000	US clinical market 2026
Typical age at FIP onset	under 2 years (majority)	Pedersen 2018

How FIP is diagnosed

No single test is 100 percent specific. The diagnosis is assembled from a set of compatible findings:

1. History and exam: a young cat (under 2 years in most cases), often from a cattery or crowded multi-cat shelter, with fluctuating fever unresponsive to antibiotics, weight loss, jaundice, ascites, or labored breathing.
2. CBC and chemistry: non-regenerative anemia, lymphopenia, hyperglobulinemia with an albumin-to-globulin (A/G) ratio under 0.4, and hyperbilirubinemia.
3. Effusion analysis: viscous yellow fluid, high in protein (over 3.5 g/dL), low in cell count (under 5,000 cells/µL), with an effusion A/G ratio under 0.4.
4. Rivalta test: an inexpensive in-house tube test. A positive result strongly suggests FIP.
5. Coronavirus PCR on effusion, cerebrospinal fluid, or tissue: detects viral RNA. Sensitivity varies by sample type.
6. Coronavirus PCR with M1058L/S1060A mutation detection: points toward mutated FIPV, though specificity remains imperfect.
7. Immunohistochemistry on a granuloma biopsy: the gold standard, but invasive and uncommon in general practice.
8. Abdominal ultrasound: mesenteric lymphadenopathy, renal or hepatic masses, visceral granulomas.

In practice, a young cat with yellow effusion, hyperglobulinemia, a low A/G ratio, and a positive Rivalta test gets treatment started before the PCR returns. Every day lost worsens the prognosis.

The 84-day protocol step by step

Phase 1: intake and start (days 1 to 7)

• Clinical confirmation of FIP-compatible disease, full bloodwork, ultrasound.
• Immediate treatment start: subcutaneous injectable GS-441524 at a dose matched to the FIP phenotype.
• Intravenous remdesivir for the first 2 to 5 days if the cat is critical (uncontrolled vomiting, severe jaundice, neurological signs), for better bioavailability and faster response.
• Hospitalization if there is severe dehydration, complete anorexia, or dyspnea from pleural effusion.
• Thoracocentesis or paracentesis if the effusion compromises breathing or causes pain.

Phase 2: outpatient treatment (days 7 to 84)

• A daily subcutaneous injection that the owner learns to give at home. Most owners use the lateral chest or flank, rotating injection sites because the drug is irritating.
• Oral alternative: GS-441524 tablets or capsules, with bioavailability around 50 percent of the injectable, so the dose is adjusted upward. More convenient but more expensive.
• Rechecks every 4 weeks: CBC, chemistry, weight. The vet watches for a gradual rise in the A/G ratio, normalization of total protein, and weight gain.
• Taper and discontinuation of any prior corticosteroid over the first two weeks.

Phase 3: closeout (days 80 to 84)

• Final injection on day 84.
• Final bloodwork: normal A/G ratio, recovered hematocrit, normal total protein.
• Ultrasound if the initial disease was granulomatous.

Phase 4: observation (weeks 13 to 24)

• No treatment.
• Clinical recheck with bloodwork at 4, 8, and 12 weeks after finishing.
• If every parameter stays normal and the cat shows no signs, it is considered cured.

Relapses, when they happen, usually appear within the first 84 days after treatment ends. If a cat relapses, a second course at a higher dose follows. The success rate after a second course stays above 70 percent.

Legal access in the US in 2026: what to know

For years, GS-441524 had no FDA approval as a veterinary drug in the United States, which pushed desperate owners into a gray market. That picture has shifted.

The compounding route

In 2024 the FDA's policy on animal drug compounding from bulk drug substances opened a legitimate path: licensed US compounding pharmacies began preparing GS-441524 for cats when prescribed by a veterinarian for an individual patient. This brought the treatment out of the shadows. A veterinarian writes the prescription, a registered pharmacy fills it, and the product comes with traceable sourcing. Cost for a full course of compounded GS-441524 runs roughly $3,000 to $10,000 for a 9 lb (4 kg) cat, depending on route (injectable versus oral) and the actual duration.

This is the clean route, and as of 2026 it is the one most US veterinarians use. It removes the central problem of the old gray market: uncertainty about what is actually in the vial.

Brands authorized outside the US

Since 2022, brands registered in the United Kingdom and Australia (Bova UK and Aura Biopharm, among others) have existed after special authorizations in those countries. They are not the standard US supply chain, but they established the regulatory precedent and the quality benchmark that the US compounding route now aims to match.

The legacy gray market

Before compounding became viable, owners sourced unbranded Asian-market product (Mutian, Hero, generic GS-441524 from unaccredited labs) through patient communities. The FIP Warriors network was the best-known of these communities: owners and volunteer administrators who guided dosing, helped people obtain product, and shared treatment experience. A full course this way cost less, in the range of $1,500 to $3,500.

What is worth understanding about that legacy market:

• These products carried no official US quality assurance. Real potency varied between lots and brands. The most widely used international brands built a reputation within the community; many others did not.
• They were not sold through pharmacies or standard veterinary clinics. A veterinarian could supervise administration, but the legal responsibility for the product's origin fell on the owner.
• With a legitimate compounding option now available, the case for the gray market has narrowed sharply. The main reason owners still consider it is price, and underdosing to save money is the single most common avoidable error.

The reality in 2026: many US FIP cures over the past several years were achieved with gray-market product under veterinary supervision, but the compounding route is now the default. The situation is in transition, and the trajectory points toward fully approved, traceable supply.

Prognosis

With a complete protocol and a dose matched to the phenotype:

• Wet, non-neurological, non-ocular FIP: cure rate 90 to 95 percent.
• Dry FIP: 80 to 90 percent.
• Ocular FIP: 80 to 90 percent at 8 to 10 mg/kg/day.
• Neurological FIP: 70 to 85 percent at 10 to 15 mg/kg/day.

Factors that worsen the prognosis:

• Critical condition at diagnosis (severe anemia, deep jaundice, encephalopathy).
• Underdosing to cut costs, the most common error in the gray market.
• Treatment stopped before day 84.
• Low-quality product with real content below the label claim.

A cured cat returns to a normal life. It is not an FIP carrier and it does not spread FIP. The disease itself is not contagious; what spreads is the intestinal FECV coronavirus, which most cats already carry. A cured cat can live with other cats without a problem.

Prevention: what is in the owner's hands

FIP has no effective vaccine. An intranasal vaccine exists, but its efficacy is heavily disputed and ISFM does not recommend it. Prevention works by reducing the chance that the enteric coronavirus (FECV) mutates in an individual cat:

1. Buy from breeders with a low viral load in the cattery. Some responsible breeders test for FECV and rotate litters to reduce prevalence.
2. Avoid stacking many simultaneous adoptions from large shelters. Overcrowding favors FECV transmission and, in turn, mutation.
3. Reduce stress in young cats: home changes, moves, spay/neuter, hospitalizations. Stress is a documented risk factor for FIPV mutation.
4. Keep strict litter box hygiene in multi-cat homes: scoop daily, empty weekly, and avoid sharing one box among many cats.
5. Isolate cats that test positive for enteric coronavirus where possible in catteries.
6. Recognize the signs early: a young cat with fever unresponsive to antibiotics, weight loss, and a distended belly is a diagnostic emergency. Every day counts.

Common questions

Is FIP contagious to other cats in the home?

Not directly, because the mutated virus lives inside the affected cat. What does transmit is the precursor enteric coronavirus (FECV), which most cats in the household already carry. There is no need to isolate the diagnosed cat.

Can it spread to humans or dogs?

No. Feline coronavirus is species-specific. It has no relationship to SARS-CoV-2 or to any pathogenic human coronavirus.

Why does the price range so widely, from $1,500 to $10,000?

Three factors: source (US compounded versus legacy gray-market Asian product), the cat's weight (the dose is per kg), and route (daily injectable, oral, or a combination with initial IV remdesivir). Compounded US product costs more than gray-market product but comes with traceable quality.

Is it legal to buy GS-441524 on my own in the US?

The clean route is a veterinary prescription filled by a licensed compounding pharmacy, which became viable after the FDA's 2024 compounding policy. Sourcing unbranded product directly for your own cat sits in a grayer area; with a legitimate prescription route now available, most veterinarians steer owners toward it.

Will my vet treat with product I supply?

Increasingly, vets do not need to, because they can prescribe compounded GS-441524 directly. Practices oriented toward feline medicine are the most comfortable managing the full protocol. If you have a legacy supply question, a cat-focused veterinarian or a board-certified internist (ACVIM) is the right person to ask.

What if the cat relapses?

A second 84-day course at a higher dose. The cure rate on a second course stays above 70 percent. A relapse is not a death sentence.

Bottom line

FIP is one of the fastest therapeutic turnarounds in modern veterinary medicine. In 2017 the diagnosis meant immediate euthanasia; by 2026 it is a treatable disease with a cure rate comparable to well-controlled serious bacterial infections. During the 84-day course, the cat needs rest and reduced stress, and recovery monitoring with bloodwork at 4-week intervals tracks the climb back to health. What is still settling in the US is the supply chain: GS-441524 moving fully into approved, traceable veterinary channels rather than depending on compounding workarounds and the legacy patient communities that filled the gap. A young cat with yellow effusion, a low A/G ratio, and a positive Rivalta test in 2026 is a case that starts protocol tomorrow. It is not a lost case.